Matt Phipps
Stock Analyst at William Blair
(0.62)
# 4,088
Out of 5,090 analysts
24
Total ratings
35.29%
Success rate
-13.83%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Matt Phipps
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| EVMN Evommune | Initiates: Outperform | n/a | $21.90 | - | 1 | Dec 1, 2025 | |
| KZR Kezar Life Sciences | Downgrades: Market Perform | n/a | $6.25 | - | 3 | Oct 17, 2025 | |
| CLYM Climb Bio | Initiates: Outperform | n/a | $1.72 | - | 1 | Oct 16, 2025 | |
| INSM Insmed | Initiates: Outperform | n/a | $204.00 | - | 1 | Aug 20, 2025 | |
| INKT MiNK Therapeutics | Downgrades: Market Perform | n/a | $11.69 | - | 2 | Jul 14, 2025 | |
| JSPR Jasper Therapeutics | Downgrades: Market Perform | n/a | $1.71 | - | 2 | Jul 7, 2025 | |
| CNTX Context Therapeutics | Initiates: Outperform | n/a | $1.05 | - | 1 | Apr 21, 2025 | |
| XNCR Xencor | Initiates: Outperform | n/a | $17.30 | - | 1 | Apr 21, 2025 | |
| GMAB Genmab | Upgrades: Outperform | n/a | $31.74 | - | 2 | Mar 11, 2025 | |
| KROS Keros Therapeutics | Downgrades: Market Perform | n/a | $21.69 | - | 1 | Dec 12, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | n/a | $27.75 | - | 1 | Nov 5, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | n/a | $9.65 | - | 1 | Sep 30, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | n/a | $10.59 | - | 1 | Apr 15, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Market Perform | n/a | $52.15 | - | 1 | Oct 27, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | n/a | $16.51 | - | 1 | Nov 14, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | n/a | $3.12 | - | 1 | Oct 21, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Outperform | n/a | $181.30 | - | 2 | Jun 8, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | n/a | $96.14 | - | 1 | Apr 8, 2021 |
Evommune
Dec 1, 2025
Initiates: Outperform
Price Target: n/a
Current: $21.90
Upside: -
Kezar Life Sciences
Oct 17, 2025
Downgrades: Market Perform
Price Target: n/a
Current: $6.25
Upside: -
Climb Bio
Oct 16, 2025
Initiates: Outperform
Price Target: n/a
Current: $1.72
Upside: -
Insmed
Aug 20, 2025
Initiates: Outperform
Price Target: n/a
Current: $204.00
Upside: -
MiNK Therapeutics
Jul 14, 2025
Downgrades: Market Perform
Price Target: n/a
Current: $11.69
Upside: -
Jasper Therapeutics
Jul 7, 2025
Downgrades: Market Perform
Price Target: n/a
Current: $1.71
Upside: -
Context Therapeutics
Apr 21, 2025
Initiates: Outperform
Price Target: n/a
Current: $1.05
Upside: -
Xencor
Apr 21, 2025
Initiates: Outperform
Price Target: n/a
Current: $17.30
Upside: -
Genmab
Mar 11, 2025
Upgrades: Outperform
Price Target: n/a
Current: $31.74
Upside: -
Keros Therapeutics
Dec 12, 2024
Downgrades: Market Perform
Price Target: n/a
Current: $21.69
Upside: -
Nov 5, 2024
Initiates: Outperform
Price Target: n/a
Current: $27.75
Upside: -
Sep 30, 2024
Initiates: Outperform
Price Target: n/a
Current: $9.65
Upside: -
Apr 15, 2024
Initiates: Outperform
Price Target: n/a
Current: $10.59
Upside: -
Oct 27, 2023
Downgrades: Market Perform
Price Target: n/a
Current: $52.15
Upside: -
Nov 14, 2022
Initiates: Outperform
Price Target: n/a
Current: $16.51
Upside: -
Oct 21, 2021
Initiates: Outperform
Price Target: n/a
Current: $3.12
Upside: -
Jun 8, 2021
Upgrades: Outperform
Price Target: n/a
Current: $181.30
Upside: -
Apr 8, 2021
Initiates: Outperform
Price Target: n/a
Current: $96.14
Upside: -